J&J’s Rybrevant Receives EU Approval for Expanded Use in NSCLC
ZacksThe European Commission approves JNJ’s Rybrevant in combination with chemotherapy for treating EGFR-mutated NSCLC following failure of prior therapy.
The European Commission approves JNJ’s Rybrevant in combination with chemotherapy for treating EGFR-mutated NSCLC following failure of prior therapy.